Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone can be included in the insured package. The reason for this advice was the placing of Sarclisa® in the so-called lock procedure for expensive medications. Sarclisa® is used to treat adult patients with multiple myeloma (MM) who have had at least one earlier therapy. The National Health Care Institute advises the Minister to temporarily include Sarclisa® in the health insurance package after price negotiations.
Registered indication
Isatuximab in combination with carfilzomib and dexamethasone is used for the treatment of adult patients with multiple myeloma (MM) who have had at least one earlier therapy. MM is a type of bone marrow cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In MM, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
The National Health Care Institute's advice
Following the multiple myeloma package advice that we issued to the Minister on 11 February 2021 we recommend that the Minister temporarily includes isatuximab in combination with carfilzomib and dexamethasone, under conditions and after competitive price negotiations, in the health care package, pending a final approach and advice from the National Health Care Institute